The important role of inflammatory biomarkers pre and post bare-metal and drug-eluting stent implantation.

In-stent restenosis and stent thrombosis are major complications after percutaneous coronary intervention and coronary stent placement. The inflammatory status of an individual, as reflected by biomarkers and genetic polymorphisms, is a strong predictor of the risk of in-stent restenosis and stent thrombosis. Identifying biomarkers and studying their values are crucial for a more efficient personalized intervention. General inflammatory biomarkers, evidence of inflammation, and the difference between inflammatory biomarkers after bare-metal stent and drug-eluting stent placement are discussed. Clinical implications and the use of antiplatelet and anti-inflammatory medications, as well as future directions in coronary intervention, in reducing the occurrence of these complications, are also discussed.